Skip to main content

Rydym wedi cadw rhai ffeiliau o'r enw cwcis ar eich dyfais. Y cwcis hyn yw:

  • Hanfodol ar gyfer y safle i weithio
  • Helpu i wella ein gwefan drwy gasglu ac adrodd gwybodaeth am sut rydych chi'n ei defnyddio

Hoffem hefyd arbed rhai cwcis i helpu i deilwra cyfathrebu.

BETA
Rydych yn edrych ar fersiwn wedi'i ddiweddaru o'r gwasanaeth hwn - bydd eich adborth yn ein helpu i'w wella.

Dyfarnu Contract

Specialised Adult whole-body MRI (WBMRI) Surveillance for Cancer Predisposing Syndromes

  • Cyhoeddwyd gyntaf: 19 Mai 2026
  • Wedi'i addasu ddiwethaf: 19 Mai 2026
  • Fersiwn: N/A
  •  

  • Efallai na fydd y ffeil hon yn gwbl hygyrch.

  •  

Eicon Gwybodaeth

Nid yw'r prynwr yn defnyddio'r wefan hon i weinyddu'r hysbysiad.

I gofnodi eich diddordeb neu gael gwybodaeth neu ddogfennau ychwanegol, darllenwch y cyfarwyddiadau yn Nhestun Llawn yr Hysbysiad. (NODER: Nid oes angen ymateb i Hysbysiadau Dyfarnu Contractau a Hysbysiadau Gwybodaeth Ymlaen Llaw fel arfer)

Cynnwys

Crynodeb

OCID:
ocds-h6vhtk-05d3d5
Cyhoeddwyd gan:
NHS England
ID Awudurdod:
AA20005
Dyddiad cyhoeddi:
19 Mai 2026
Dyddiad Cau:
-
Math o hysbysiad:
Dyfarnu Contract
Mae ganddo ddogfennau:
Nac Ydi
Wedi SPD:
Nac Ydi
Mae ganddo gynllun lleihau carbon:
AMH

Crynodeb

This is a notice of intention to make an award. NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU),on behalf of NHS England Specialised Commissioning (referred to as the Authority) invited suitably qualified and experienced providers to express interest in the provision of Specialised Adult whole-body MRI (WBMRI) Surveillance for Cancer Predisposing Syndromes by responding to this accreditation process.<br/><br/>Services are being commissioned across seven (7) geographical regions to serve the population of England, as outlined below:<br/><br/>Lot 1: London<br/>Lot 2: East of England<br/>Lot 3: South East<br/>Lot 4: South West<br/>Lot 5: Midlands<br/>Lot 6: North East and Yorkshire<br/>Lot 7: North West<br/><br/>- There is no restriction on the number of sites that may be commissioned.<br/>- Providers must be located in and deliver services from the defined geographical area(s) that they are interested in providing services to.<br/><br/>Link to NHS England Regions:<br/>NHS England » Regional teams (https://www.england.nhs.uk/about/regional-area-teams/).<br/><br/>Inherited cancer predisposition syndromes are genetic conditions that increase the risk of developing one or more types of cancer. Scanning will be commissioned for three rare inherited cancer predisposition syndromes; Li-Fraumeni syndrome (LFS), constitutional mismatch repair deficiency syndrome (CMMRD) and rhabdoid tumour predisposition syndrome (RTPS).<br/><br/>Published clinical guidelines for these conditions recommend the use of regular whole-body MRI (WBMRI) with the aim of detecting cancers at an early stage. The provision of expanded capacity for WBMRI scanning aims to improve clinical care of individuals once an inherited cancer predisposition has been diagnosed.<br/><br/>Providers will:<br/>• Provide, interpret and report WB-MRI Scanning for the patient cohort described.<br/>• Provide, interpret, and report brain MRI Scanning (the first one with contrast when possible).<br/>• Establish effective pathways (including sharing results) with providers.<br/>• Be linked to regional genetic centres to allow continuity of care.<br/>• Facilitate communication with referrers including consultant clinical geneticists<br/>• Have capacity to plan and undertake WBMRI under general anaesthetic if re-quired.<br/>• Have information governance processes that permit sharing clinical and imaging data across organisations involved with providing a cancer surveillance service, and collection of clinical outcome and monitoring data.<br/>• Engage positively with associated patient support groups.<br/>• Ensure clear communication with Genetics Services and patients, to support patients to make decisions on where to access screening.<br/>• Work collaboratively with other organisations e.g. within imaging networks, to provide scanning and reporting capacity and expertise to meet the needs of their population including transition between paediatric and adult services.<br/>• Operate Quality Assessment processes according to CQC standards<br/>• Screening will be in addition to breast screening undertaken through the National VHRS Programme<br/>• Provide facilities will be in line with NHS guidance on Facilities for diagnostic imaging and interventional radiology.<br/>• Support continued educational initiatives for non-genetics healthcare professionals to improve expertise and understanding of cancer predisposition syndromes.<br/>• Liaise with partners across cancer alliances to support early diagnosis innovation opportunities<br/>• Ensure screening frequency will be in accordance with surveillance protocols.

Testun llawn y rhybydd

Hysbysiad dyfarnu contract

Canlyniadau'r weithdrefn gaffael

Adran I: Endid contractio

I.1) Enw a chyfeiriad

NHS England

Wellington House, 133-135 Waterloo Rd

London

SE1 8UG

UK

Person cyswllt: Jessica Gaucher-Thompson

E-bost: j.gaucher-thompson@nhs.net

NUTS: UKI

Cyfeiriad(au) rhyngrwyd

Prif gyfeiriad: https://www.england.nhs.uk/

Cyfeiriad proffil y prynwr: https://www.england.nhs.uk/

I.4) Y math o awdurdod contractio

Corff a lywodraethir gan gyfraith gyhoeddus

I.5) Prif weithgaredd

Iechyd

Adran II: Gwrthrych

II.1) Cwmpas y caffaeliad

II.1.1) Teitl

Specialised Adult whole-body MRI (WBMRI) Surveillance for Cancer Predisposing Syndromes

II.1.2) Prif god CPV

85100000

 

II.1.3) Y math o gontract

Gwasanaethau

II.1.4) Disgrifiad byr

This is a notice of intention to make an award. NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU),on behalf of NHS England Specialised Commissioning (referred to as the Authority) invited suitably qualified and experienced providers to express interest in the provision of Specialised Adult whole-body MRI (WBMRI) Surveillance for Cancer Predisposing Syndromes by responding to this accreditation process.<br/><br/>Services are being commissioned across seven (7) geographical regions to serve the population of England, as outlined below:<br/><br/>Lot 1: London<br/>Lot 2: East of England<br/>Lot 3: South East<br/>Lot 4: South West<br/>Lot 5: Midlands<br/>Lot 6: North East and Yorkshire<br/>Lot 7: North West<br/><br/>- There is no restriction on the number of sites that may be commissioned.<br/>- Providers must be located in and deliver services from the defined geographical area(s) that they are interested in providing services to.<br/><br/>Link to NHS England Regions:<br/>NHS England » Regional teams (https://www.england.nhs.uk/about/regional-area-teams/).<br/><br/>Inherited cancer predisposition syndromes are genetic conditions that increase the risk of developing one or more types of cancer. Scanning will be commissioned for three rare inherited cancer predisposition syndromes; Li-Fraumeni syndrome (LFS), constitutional mismatch repair deficiency syndrome (CMMRD) and rhabdoid tumour predisposition syndrome (RTPS).<br/><br/>Published clinical guidelines for these conditions recommend the use of regular whole-body MRI (WBMRI) with the aim of detecting cancers at an early stage. The provision of expanded capacity for WBMRI scanning aims to improve clinical care of individuals once an inherited cancer predisposition has been diagnosed.<br/><br/>Providers will:<br/>• Provide, interpret and report WB-MRI Scanning for the patient cohort described.<br/>• Provide, interpret, and report brain MRI Scanning (the first one with contrast when possible).<br/>• Establish effective pathways (including sharing results) with providers.<br/>• Be linked to regional genetic centres to allow continuity of care.<br/>• Facilitate communication with referrers including consultant clinical geneticists<br/>• Have capacity to plan and undertake WBMRI under general anaesthetic if re-quired.<br/>• Have information governance processes that permit sharing clinical and imaging data across organisations involved with providing a cancer surveillance service, and collection of clinical outcome and monitoring data.<br/>• Engage positively with associated patient support groups.<br/>• Ensure clear communication with Genetics Services and patients, to support patients to make decisions on where to access screening.<br/>• Work collaboratively with other organisations e.g. within imaging networks, to provide scanning and reporting capacity and expertise to meet the needs of their population including transition between paediatric and adult services.<br/>• Operate Quality Assessment processes according to CQC standards<br/>• Screening will be in addition to breast screening undertaken through the National VHRS Programme<br/>• Provide facilities will be in line with NHS guidance on Facilities for diagnostic imaging and interventional radiology.<br/>• Support continued educational initiatives for non-genetics healthcare professionals to improve expertise and understanding of cancer predisposition syndromes.<br/>• Liaise with partners across cancer alliances to support early diagnosis innovation opportunities<br/>• Ensure screening frequency will be in accordance with surveillance protocols.

II.1.6) Gwybodaeth am lotiau

Mae’r contract hwn wedi’i rannu’n lotiau: Na

II.1.7) Cyfanswm gwerth y caffaeliad

Gwerth heb gynnwys TAW: 1 387 430.00 GBP

II.2) Disgrifiad

II.2.2) Cod(au) CPV ychwanegol

85100000

II.2.3) Man cyflawni

Cod NUTS:

UKC

UKD

UKE

UKF

UKG

UKH

UKI

UKJ

UKK

II.2.4) Disgrifiad o’r caffaeliad

This notice sets out the intention to award a contract following a competitive procurement process for the provision of Specialised Adult whole-body MRI (WBMRI) Surveillance for Cancer Predisposing Syndromes.<br/><br/>The Commissioner intends to award 10 individual contracts for this newly commissioned service, following this competitive process, to providers not previously contracted for this service.<br/><br/>Inherited cancer predisposition syndromes are genetic conditions that increase the risk of developing one or more types of cancer. Scanning will be commissioned for three rare inherited cancer predisposition syndromes; Li-Fraumeni syndrome (LFS), constitutional mismatch repair deficiency syndrome (CMMRD) and rhabdoid tumour predisposition syndrome (RTPS).<br/><br/>Published clinical guidelines for these conditions recommend the use of regular whole-body MRI (WBMRI) with the aim of detecting cancers at an early stage. The provision of expanded capacity for WBMRI scanning aims to improve clinical care of individuals once an inherited cancer predisposition has been diagnosed.<br/><br/>Providers will:<br/>• Provide, interpret and report WB-MRI Scanning for the patient cohort described.<br/>• Provide, interpret, and report brain MRI Scanning (the first one with contrast when possible).<br/>• Establish effective pathways (including sharing results) with providers.<br/>• Be linked to regional genetic centres to allow continuity of care.<br/>• Facilitate communication with referrers including consultant clinical geneticists<br/>• Have capacity to plan and undertake WBMRI under general anaesthetic if re-quired.<br/>• Have information governance processes that permit sharing clinical and imaging data across organisations involved with providing a cancer surveillance service, and collection of clinical outcome and monitoring data.<br/>• Engage positively with associated patient support groups.<br/>• Ensure clear communication with Genetics Services and patients, to support patients to make decisions on where to access screening.<br/>• Work collaboratively with other organisations e.g. within imaging networks, to provide scanning and reporting capacity and expertise to meet the needs of their population including transition between paediatric and adult services.<br/>• Operate Quality Assessment processes according to CQC standards<br/>• Screening will be in addition to breast screening undertaken through the National VHRS Programme<br/>• Provide facilities will be in line with NHS guidance on Facilities for diagnostic imaging and interventional radiology.<br/>• Support continued educational initiatives for non-genetics healthcare professionals to improve expertise and understanding of cancer predisposition syndromes.<br/>• Liaise with partners across cancer alliances to support early diagnosis innovation opportunities<br/>• Ensure screening frequency will be in accordance with surveillance protocols.<br/><br/>The approximate total lifetime value of all 10 contracts over the full 5 year contract term is circa £1,387,430.<br/><br/>The services are intended to commence on 1 July 2026, with an initial contract period to 30 June 2029, and an option to extend for up to a further two years, resulting in a maximum contract term of five years.<br/><br/>The intention to to award contracts to the following providers:<br/>Lot 1 - London<br/>Guy's and St Thomas' NHS Foundation Trust<br/>London North West University Healthcare NHS Trust<br/>The Royal Marsden NHS Foundation Trust<br/>Lot 2 – East of England<br/>Cambridge University Hospitals NHS Foundation Trust<br/>Lot 3 - South East<br/>University Hospitals Southampton NHS Foundation Trust<br/>Lot 4 – South West<br/>Royal Devon University Hospitals Trust<br/>Lot 5 – Midlands<br/>Nottingham University Hospitals NHS Trust Primary<br/>Lot 6 - North East and Yorkshire<br/>Leeds Teaching Hospitals NHS Trust<br/>Sheffield Teaching Hospitals NHS Foundation Trust<br/>Lot 7 - North West<br/>Manchester University NHS Foundation Trust (MFT)

II.2.5) Meini prawf dyfarnu

Maes prawf ansawdd: Key Criteria / Pwysoliad: Pass/Fail

Price / Pwysoliad:  0

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Ydy

Disgrifiad o’r opsiynau:

Initial period of three (3) years with the Commissioner having the option to extend the Contract for up to a further two (2) years (maximum contract duration 5 years)

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

II.2.14) Gwybodaeth ychwanegol

This is a Provider Selection Regime (PSR) intention to award notice. The awarding of these contracts is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Procurement Act Regulations 2023 do not apply to this award. The standstill period begins on the day after the publication of this notice. <br/><br/>Representations by providers must be made to the relevant authority by Friday 29 May 2026. These contracts have not yet formally been awarded; this notice serves as an intention to award under the PSR. Representations should be sent to jessica.gaucher-thompson@nhs.net.<br/><br/>The award decision‑makers were NHS England’s National Commissioning Group (NCG). <br/><br/>The award decision was based on the outcome of a pass/fail evaluation against the published procurement requirements.<br/><br/>All key award criteria were assessed on a pass/fail basis and were considered of equal importance.<br/><br/>The providers selected for award successfully met all pass/fail requirements and were therefore assessed as compliant with the mandatory criteria.

Section IV: Gweithdrefn

IV.1) Disgrifiad

IV.1.1) Y math o weithdrefn

Gweithdrefn agored

IV.1.8) Gwybodaeth am Gytundeb Caffael y Llywodraeth (GPA)

The procurement is covered by the Government Procurement Agreement: Ydy

IV.2) Gwybodaeth weinyddol

IV.2.1) Cyhoeddiad blaenorol mewn perthynas â’r weithdrefn hon

Rhif yr hysbysiad yn OJ S:

2025/S 000-068396

Section V: Dyfarnu contract

Dyfernir contract/lot: Ydy

V.2 Dyfarnu contract

V.2.1) Y dyddiad y daeth y contract i ben

21/04/2026

V.2.2) Gwybodaeth am dendrau

Nifer y tendrau a ddaeth i law: 14

Nifer y tendrau a ddaeth i law gan BBaChau: 3

Dyfarnwyd y contract i gr?p o weithredwyr economaidd: Na

V.2.3) Enw a chyfeiriad y contractwr

Leeds Teaching Hospitals NHS Trust

00000N/A

Trust Headquarters, Beckett St, Harehills, Leeds

Leeds

LS9 7TF

UK

E-bost: leedsth-tr.btlw@nhs.net

NUTS: UK

BBaCh yw’r contractwr: Na

V.2.4) Gwybodaeth am werth y contract/lot (heb gynnwys VAT)

Amcangyfrif cychwynnol o gyfanswm gwerth y contract/lot: 1 387 420.00 GBP

Cyfanswm gwerth y contract/lot: 154 640.00 GBP

V.2.5) Gwybodaeth am is-gontractio

Section V: Dyfarnu contract

Dyfernir contract/lot: Ydy

V.2 Dyfarnu contract

V.2.1) Y dyddiad y daeth y contract i ben

21/04/2026

V.2.2) Gwybodaeth am dendrau

Nifer y tendrau a ddaeth i law: 14

Nifer y tendrau a ddaeth i law gan BBaChau: 3

Dyfarnwyd y contract i gr?p o weithredwyr economaidd: Na

V.2.3) Enw a chyfeiriad y contractwr

London North West University Healthcare NHS Trust

LNWH Harrow Middlesex

London

HA1 3UJ

UK

NUTS: UKI

BBaCh yw’r contractwr: Na

V.2.4) Gwybodaeth am werth y contract/lot (heb gynnwys VAT)

Amcangyfrif cychwynnol o gyfanswm gwerth y contract/lot: 1 387 420.00 GBP

Cyfanswm gwerth y contract/lot: 157 630.00 GBP

V.2.5) Gwybodaeth am is-gontractio

Section V: Dyfarnu contract

Dyfernir contract/lot: Ydy

V.2 Dyfarnu contract

V.2.1) Y dyddiad y daeth y contract i ben

21/04/2026

V.2.2) Gwybodaeth am dendrau

Nifer y tendrau a ddaeth i law: 14

Nifer y tendrau a ddaeth i law gan BBaChau: 3

Dyfarnwyd y contract i gr?p o weithredwyr economaidd: Na

V.2.3) Enw a chyfeiriad y contractwr

Royal Devon University Hospitals Trust

Barrack Road, Exeter Devon

Devon

EX2 5DW

UK

Ffôn: +44 7816525793

NUTS: UKK4

BBaCh yw’r contractwr: Na

V.2.4) Gwybodaeth am werth y contract/lot (heb gynnwys VAT)

Amcangyfrif cychwynnol o gyfanswm gwerth y contract/lot: 1 387 420.00 GBP

Cyfanswm gwerth y contract/lot: 87 100.00 GBP

V.2.5) Gwybodaeth am is-gontractio

Section V: Dyfarnu contract

Dyfernir contract/lot: Ydy

V.2 Dyfarnu contract

V.2.1) Y dyddiad y daeth y contract i ben

21/04/2026

V.2.2) Gwybodaeth am dendrau

Nifer y tendrau a ddaeth i law: 14

Nifer y tendrau a ddaeth i law gan BBaChau: 3

Dyfarnwyd y contract i gr?p o weithredwyr economaidd: Na

V.2.3) Enw a chyfeiriad y contractwr

The Royal Marsden NHS Foundation Trust

00000N/A

Fulham Road, London

London

SW3 6JJ

UK

Ffôn: +44 7402903350

NUTS: UKI

BBaCh yw’r contractwr: Na

V.2.4) Gwybodaeth am werth y contract/lot (heb gynnwys VAT)

Amcangyfrif cychwynnol o gyfanswm gwerth y contract/lot: 1 387 420.00 GBP

Cyfanswm gwerth y contract/lot: 184 070.00 GBP

V.2.5) Gwybodaeth am is-gontractio

Section V: Dyfarnu contract

Dyfernir contract/lot: Ydy

V.2 Dyfarnu contract

V.2.1) Y dyddiad y daeth y contract i ben

21/04/2026

V.2.2) Gwybodaeth am dendrau

Nifer y tendrau a ddaeth i law: 14

Nifer y tendrau a ddaeth i law gan BBaChau: 3

Dyfarnwyd y contract i gr?p o weithredwyr economaidd: Na

V.2.3) Enw a chyfeiriad y contractwr

Guy's and St Thomas' NHS Foundation Trust

00000N/A

Great Maze Pond. London

London

SE1 9RT

UK

NUTS: UKL12

BBaCh yw’r contractwr: Na

V.2.4) Gwybodaeth am werth y contract/lot (heb gynnwys VAT)

Amcangyfrif cychwynnol o gyfanswm gwerth y contract/lot: 1 387 420.00 GBP

Cyfanswm gwerth y contract/lot: 222 215.00 GBP

V.2.5) Gwybodaeth am is-gontractio

Section V: Dyfarnu contract

Dyfernir contract/lot: Ydy

V.2 Dyfarnu contract

V.2.1) Y dyddiad y daeth y contract i ben

21/04/2026

V.2.2) Gwybodaeth am dendrau

Nifer y tendrau a ddaeth i law: 14

Nifer y tendrau a ddaeth i law gan BBaChau: 3

Dyfarnwyd y contract i gr?p o weithredwyr economaidd: Na

V.2.3) Enw a chyfeiriad y contractwr

Cambridge University Hospitals NHS Foundation Trust

00000N/A

Hills Road, Cambridge

Cambridge

CB2 0QQ

UK

NUTS: UKH12

BBaCh yw’r contractwr: Na

V.2.4) Gwybodaeth am werth y contract/lot (heb gynnwys VAT)

Amcangyfrif cychwynnol o gyfanswm gwerth y contract/lot: 1 387 420.00 GBP

Cyfanswm gwerth y contract/lot: 92 460.00 GBP

V.2.5) Gwybodaeth am is-gontractio

Section V: Dyfarnu contract

Dyfernir contract/lot: Ydy

V.2 Dyfarnu contract

V.2.1) Y dyddiad y daeth y contract i ben

21/04/2026

V.2.2) Gwybodaeth am dendrau

Nifer y tendrau a ddaeth i law: 14

Nifer y tendrau a ddaeth i law gan BBaChau: 3

Dyfarnwyd y contract i gr?p o weithredwyr economaidd: Na

V.2.3) Enw a chyfeiriad y contractwr

Manchester University NHS Foundation Trust (MFT)

N\A

Trust Headquarters Cobbett House Oxford Road Manchester

Manchester

M13 9WL

UK

NUTS: UKD33

BBaCh yw’r contractwr: Na

V.2.4) Gwybodaeth am werth y contract/lot (heb gynnwys VAT)

Amcangyfrif cychwynnol o gyfanswm gwerth y contract/lot: 1 387 420.00 GBP

Cyfanswm gwerth y contract/lot: 211 395.00 GBP

V.2.5) Gwybodaeth am is-gontractio

Section V: Dyfarnu contract

Dyfernir contract/lot: Ydy

V.2 Dyfarnu contract

V.2.1) Y dyddiad y daeth y contract i ben

21/04/2026

V.2.2) Gwybodaeth am dendrau

Nifer y tendrau a ddaeth i law: 14

Nifer y tendrau a ddaeth i law gan BBaChau: 3

Dyfarnwyd y contract i gr?p o weithredwyr economaidd: Na

V.2.3) Enw a chyfeiriad y contractwr

University Hospitals Southampton

Tremona Road Southampton

Southampton

SO16 6YD

UK

NUTS: UKJ32

BBaCh yw’r contractwr: Na

V.2.4) Gwybodaeth am werth y contract/lot (heb gynnwys VAT)

Amcangyfrif cychwynnol o gyfanswm gwerth y contract/lot: 1 387 420.00 GBP

Cyfanswm gwerth y contract/lot: 102 085.00 GBP

V.2.5) Gwybodaeth am is-gontractio

Section V: Dyfarnu contract

Dyfernir contract/lot: Ydy

V.2 Dyfarnu contract

V.2.1) Y dyddiad y daeth y contract i ben

21/04/2026

V.2.2) Gwybodaeth am dendrau

Nifer y tendrau a ddaeth i law: 14

Nifer y tendrau a ddaeth i law gan BBaChau: 3

Dyfarnwyd y contract i gr?p o weithredwyr economaidd: Na

V.2.3) Enw a chyfeiriad y contractwr

Sheffield Teaching Hospitals NHS Foundation Trust

00000N/A

8 Beech Hill Road

Sheffield

S10 2SB

UK

E-bost: kirsty.mallalieu@nhs.net

NUTS: UK

BBaCh yw’r contractwr: Na

V.2.4) Gwybodaeth am werth y contract/lot (heb gynnwys VAT)

Amcangyfrif cychwynnol o gyfanswm gwerth y contract/lot: 1 387 420.00 GBP

Cyfanswm gwerth y contract/lot: 87 465.00 GBP

V.2.5) Gwybodaeth am is-gontractio

Section V: Dyfarnu contract

Dyfernir contract/lot: Ydy

V.2 Dyfarnu contract

V.2.1) Y dyddiad y daeth y contract i ben

21/04/2026

V.2.2) Gwybodaeth am dendrau

Nifer y tendrau a ddaeth i law: 14

Nifer y tendrau a ddaeth i law gan BBaChau: 3

Dyfarnwyd y contract i gr?p o weithredwyr economaidd: Na

V.2.3) Enw a chyfeiriad y contractwr

Nottingham University Hospitals NHS Trust Primary

00000N/A

City Hospital Campus, Hucknall Road,

Nottingham

NG5 1PB

UK

E-bost: invoices.trade@nuh.nhs.uk

NUTS: UKF14

BBaCh yw’r contractwr: Na

V.2.4) Gwybodaeth am werth y contract/lot (heb gynnwys VAT)

Amcangyfrif cychwynnol o gyfanswm gwerth y contract/lot: 1 387 420.00 GBP

Cyfanswm gwerth y contract/lot: 88 370.00 GBP

V.2.5) Gwybodaeth am is-gontractio

Section VI: Gwybodaeth ategol

VI.4) Gweithdrefnau adolygu

VI.4.1) Corff adolygu

NHS Arden and Greater East Midlands Commissioning Support Unit

Cardinal Square, 10 Nottingham Road

Derby

DE1 3QT

UK

Cyfeiriad(au) rhyngrwyd

URL: https://www.ardengemcsu.nhs.uk/

VI.4.3) Gweithdrefn adolygu

Gwybodaeth fanwl gywir am y terfyn(au) amser ar gyfer gweithdrefnau adolygu:

Representations by providers must be made to the relevant authority by Friday 29 May 2026. These contracts have not yet formally been awarded; this notice serves as an intention to award under the PSR. Representations should be sent to jessica.gaucher-thompson@nhs.net.

VI.5) Dyddiad anfon yr hysbysiad hwn

18/05/2026

Codio

Categorïau nwyddau

ID Teitl Prif gategori
85100000 Gwasanaethau iechyd Gwasanaethau iechyd a gwaith cymdeithasol

Lleoliadau Dosbarthu

ID Disgrifiad
100 DU - I gyd

Cyfyngiadau Rhanbarthol ar y Rhybuddion

Mae’r prynwr wedi cyfyngu’r rhybuddion ar gyfer yr hysbysiad hwn i gyflenwyr yn y rhanbarthau canlynol.

ID Disgrifiad
Nid oes cyfyngiadau ar y rhybuddion ar gyfer yr hysbysiad hwn.

Ynglŷn â'r prynwr

Prif gyswllt:
j.gaucher-thompson@nhs.net
Cyswllt gweinyddol:
N/a
Cyswllt technegol:
N/a
Cyswllt arall:
N/a

Gwybodaeth bellach

Dyddiad Manylion
Nid oes unrhyw wybodaeth bellach wedi'i lanlwytho.

0800 222 9004

Mae'r llinellau ar agor rhwng 8:30am a 5pm o ddydd Llun i ddydd Gwener.

Rydym yn croesawu galwadau'n Gymraeg.

We welcome calls in Welsh.